250 related articles for article (PubMed ID: 24738598)
1. Coexistence of three variants of cutaneous mastocytosis as the presenting sign of systemic mastocytosis with somatic c-kit D816V point mutation.
Lesnoni La Parola I; Cannistraci C; Izzi S; Pisani F; Amantea A; Rongioletti F
Int J Dermatol; 2014 Oct; 53(10):1265-8. PubMed ID: 24738598
[No Abstract] [Full Text] [Related]
2. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease.
Carter MC; Bai Y; Ruiz-Esteves KN; Scott LM; Cantave D; Bolan H; Eisch R; Sun X; Hahn J; Maric I; Metcalfe DD
Br J Haematol; 2018 Dec; 183(5):775-782. PubMed ID: 30488427
[TBL] [Abstract][Full Text] [Related]
3. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
4. New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood.
Czarny J; Żuk M; Zawrocki A; Plata-Nazar K; Biernat W; Niedoszytko M; Ługowska-Umer H; Nedoszytko B; Wasąg B; Nowicki RJ; Lange M
Acta Derm Venereol; 2020 May; 100(10):adv00149. PubMed ID: 32399575
[TBL] [Abstract][Full Text] [Related]
5. [Clinical observations in cutan mastocytosis].
Mihalik N; Hidvégi B; Hársing J; Várkonyi J; Csomor J; Kovalszky I; Marschalkó M; Kárpáti S
Orv Hetil; 2013 Sep; 154(37):1469-75. PubMed ID: 24016753
[TBL] [Abstract][Full Text] [Related]
6. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
[TBL] [Abstract][Full Text] [Related]
7. Mastocytosis.
Abid A; Malone MA; Curci K
Prim Care; 2016 Sep; 43(3):505-18. PubMed ID: 27545739
[TBL] [Abstract][Full Text] [Related]
8. [Mastocytosis: revisited with new cytogenetic data].
Vaes M; Vereecken P; de Wind R; Andry G; Li R; Bron D
Rev Med Brux; 2012; 33(1):12-21. PubMed ID: 22512145
[TBL] [Abstract][Full Text] [Related]
9. The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry.
Merante S; Ferretti VV; Elena C; Brazzelli V; Zanotti R; Neri I; Magliacane D; Belloni Fortina A; Ingeborg F; Pastorello EA; Pieri L; Papayannidis C; Mauro M; Grifoni F; Minelli R; Guggiari E; Difonzo E; Bocchia M; Caroppo F; Di Nuzzo S; Elli EM; Rondoni M; Ciccocioppo R; Di Stefano M; Bossi G; Boveri E; Bonadonna P; Giona F; Valent P; Triggiani M
Future Oncol; 2018 Nov; 14(26):2713-2723. PubMed ID: 30207489
[TBL] [Abstract][Full Text] [Related]
10. c-KIT-Positive Fatal Diffuse Cutaneous Mastocytosis With Systemic Manifestations in a Neonate.
Chaudhary N; Shapiro N; Bhutada A; Rastogi S
J Pediatr Hematol Oncol; 2019 Jul; 41(5):e338-e340. PubMed ID: 30067557
[TBL] [Abstract][Full Text] [Related]
11. Mastocytosis and related disorders.
Chiu A; Orazi A
Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
[TBL] [Abstract][Full Text] [Related]
12. [Anaphylactoid reaction in occult systemic mastocytosis. A rare dermatologic emergency ].
Ständer H; Beier K; Metze D; Brehler R
Hautarzt; 2005 Mar; 56(3):265-9. PubMed ID: 15619082
[TBL] [Abstract][Full Text] [Related]
13. Telangiectasia macularis eruptiva perstans: an old terminology, still frequently used.
Wilmas K; Wohlmuth-Wieser I; Duvic M
Dermatol Online J; 2017 Aug; 23(8):. PubMed ID: 29469737
[TBL] [Abstract][Full Text] [Related]
14. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
15. The genetic basis of mast cell activation disease - looking through a glass darkly.
Molderings GJ
Crit Rev Oncol Hematol; 2015 Feb; 93(2):75-89. PubMed ID: 25305106
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
17. [Systemic mastocytosis: bone impact].
Spivacow FR; Sarli M; Nakutny R
Medicina (B Aires); 2012; 72(3):201-6. PubMed ID: 22763156
[TBL] [Abstract][Full Text] [Related]
18. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
19. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic challenge in a patient with severe pruritic rash.
Manea I; Ailenei E; Candrea E; Dima D; Deleanu D
Ann Allergy Asthma Immunol; 2015 Jan; 114(1):65-7. PubMed ID: 25457869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
